ArticleJournal of pediatric gastroenterology and nutrition2026
Bowel ultrasound scan in the management of pediatric moderate ulcerative colitis: The applicability of international bowel ultrasound segmental activity score.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Update on intestinal ultrasound in pediatric inflammatory bowel disease.European journal of pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo evaluate bowel ultrasound (BUS) findings and the diagnostic and prognostic performance of international bowel ultrasound segmental activity score (IBUS-SAS) in children with moderate ulcerative colitis (UC), including its accuracy for assessing endoscopic activity and predicting clinical remission and colectomy within 12 months.
methodsThis was a single-center retrospective study conducted at Meyer Children's Hospital IRCCS. All patients who underwent a BUS performed for moderate UC (defined as pediatric ulcerative colitis activity index 35-60, either at disease onset or at relapse) between January 2019 and December 2023 were included. Where available, data on ileocolonoscopy performed within 4 weeks before or after BUS were retrieved, if no changes in medical management were performed during this period.
resultsSeventy-seven patients were included; 35/77 (45.5%) underwent ileocolonoscopy within 4 weeks from BUS. The most common BUS finding was increased colonic wall thickness (74/77, 96.1%), followed by enhanced vascularization (70/77, 90.9%). Loss of wall stratification was observed in 15 of 77 BUS (19.5%). The discriminative ability of IBUS-SAS in identifying moderate endoscopic activity was appraised through a receiver operating characteristic curve, showing a good area under the curve (0.75, 95% confidence interval [CI]: 0.58-0.90, p = 0.021) with an optimal cut-off of 48.5. IBUS-SAS ≥ 49 (as nominal variable) was identified as independent predictor of clinical remission (adjusted hazard ratio:0.42, 95% CI: 0.23-0.78) and colectomy within 12 months (adjusted odds ratio:4.18, 95% CI: 1.03-16.91).
conclusionsBUS is a non-invasive, repeatable tool for monitoring disease activity and stratifying pediatric UC with moderate activity. IBUS-SAS showed good discriminative ability for endoscopic activity, supporting its use for ultrasound-based risk-stratification in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.